Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2

Journal of Immunological Methods

Volumn 230, Issue 1-2, 1999, Pages 159-171

  Lu, Dan ^a   Kotanides, Helen ^a   Jimenez, Xenia ^a   Zhou, Qinwei ^a   Persaud, Kris ^a   Bohlen, Peter ^a   Witte, Larry ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Antibody engineering; Bispecific antibody; Diabody; Single chain Fv; VEGF KDR Flk 1

Indexed keywords

BISPECIFIC ANTIBODY; EPITOPE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

AFFINITY CHROMATOGRAPHY; ANGIOGENESIS; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BIOENGINEERING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EXPRESSION VECTOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEREOSPECIFICITY;

ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE; EPITOPES; ESCHERICHIA COLI; HUMANS; IMMUNOLOGIC TECHNIQUES; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 0032737901     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00135-0     Document Type: Article

References (37)

1. Brown, L.F., Detmar, M., Claffey, K., Nagy, J.A., Feng, D., Dvorak, A.M., Dvorak, H.F., 1997. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: Goldberg, I.D., Rosen, E.M. (Eds.), Regulation of Angiogenesis. Birkhauser Verlag, Basel, Switzerland, p. 233.
2. Carter P., Ridgway J., Zhu Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother. 4:1995;463.
3. Cheong H.S., Chang J.S., Park J.M., Byun S.M. Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem. Biophys. Res. Commun. 173:1990;795.
4. Colman P.M., Deisenhofer J., Huber R., Palm W. Structure of the human antibody molecule Kol (immunoglobulin G1): an electron density map at 5 Å resolution. J. Mol. Biol. 100:1976;257.
5. Curnow R.T. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol. Immunother. 45:1997;210.
6. De Gast G.C., van de Winkel J.G.J., Bast B.E.J.E.J. Clinical perspectives of bispecific antibodies in cancer. Cancer Immunol. Immunother. 45:1997;121.
7. De Kruif J., Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem. 271:1996;7630.
8. Ehrlich P.H., Moyle W.R., Moustafa Z.A., Canfield R.E. Mixing two monoclonal antibodies yielded enhanced affinity for antigen. J. Immunol. 128:1982;2709.
9. Fanger, M.W., Morganelli, P.M., Guyre, P.M., 1993. Use of bispecific antibodies in the therapy of tumors. In: Rosen, Steven, T., Kuzel, T.M. (Eds.), Immunoconjugate Therapy of Hematologic Malignancies. Kluwer Academic Publishers, p. 181.
10. FitzGerald K., Holliger P., Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng. 10:1997;1221.
11. Fuh G., Li B., Crowley C., Cunningham B., Wells J.A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273:1998;11197.
12. Harris L.J., Larson S.B., Hasel K.W., Day J., Greenwood A., McPherson A. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature. 360:1992;369.
13. Holliger P., Winter G. Engineering bispecific antibodies. Curr. Opin. Biotechnol. 4:1993;446.
14. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6444.
15. Holmes N.J., Parham P. Enhancement of monoclonal antibodies against HLA-A2 is due to antibody bivalency. J. Biol. Chem. 258:1983;1580.
16. Kaplan J.B., Sridharan L., Zaccardi J.A., Dougher-Vermazen M., Terman B.I. Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera. Growth Factors. 14:1997;243.
17. Merchant A.M., Zhu Z., Yuan J., Goddard A., Adams C.W., Presta L.G., Carter P. An efficient route to human bispecific IgG. Nat. Biotechnol. 16:1998;677.
18. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P.H., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835.
19. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London). 367:1994;576.
20. Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C., de Vos A.M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. U.S.A. 94:1997;7192.
21. Neri D., Mono M., Prospero T., Winter G. High-affinity antigen binding by chelating recombinant antibodies. J. Mol. Biol. 246:1995;367.
22. Perisic O., Webb P.A., Holliger P., Winter G., Williams R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 2:1994;1217.
23. Picken R.N., Mazaitis A.J., Maas W.K., Rey M., Heyneker H. Nucleotide sequence of the gene for heat-stable enterotoxin II of Escherichia coli. Infect. Immun. 42:1983;269.
24. Plate K.H., Breier G., Millauer B., Ullrich A., Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53:1993;5822.
25. Pluckthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:1997;83.
26. Renner C., Jung W., Sahin U., Denfeld R., Pohl C., Trumper L., Hartmann F., Diehl V., van Lier R., Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 264:1994;833.
27. H3 domains for heavy chain heterodimerization. Protein Eng. 9:1996;617.
28. Sarma V.R., Silverton E.W., Sheriff S., Cohen G.H., Smith-Gill S.J., Davies D.R. The three-dimensional structure at 6 Å resolution of a human γG1 immunoglobulin molecule. J. Biol. Chem. 246:1971;3753.
29. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimtrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase receptor as a receptor for vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579.
30. Weiner L.M., Alpaugh R.K., von Mehren M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol. Immunother. 45:1997;190.
31. Whitlow M., Filpula D., Rollence M.L., Feng S.L., Wood J.F. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. Protein Eng. 7:1994;1017.
32. Witte L., Hicklin D.J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis. Rev. 17:1998;155.
33. HER2 overexpressing tumor cells. Int. J. Cancer. 62:1995;319.
34. Zhu Z., Zapata G., Shalaby M.R., Snedecor B., Chen H., Carter P. High level secretion of a humanized bispecific diabody from Escherichia coli. Bio/Technology. 14:1996;192.
35. Zhu Z., Presta L.G., Zapata G., Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6:1997;781.
36. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single chain antibodies from a phage display library. Cancer Res. 58:1998;3209.
37. Zhu Z., Lu D., Kotanides H., Santiago A., Jimenez X., Simcox T., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. 136:1999;203.